08:00 , Feb 6, 2012 |  BioCentury  |  Finance

DBV readies IPO

French allergy play DBV Technologies is the second company this year to announce plans for an IPO on Euronext Paris. DBV has filed its "document de base," the French equivalent of a preliminary prospectus. Once...
08:00 , Nov 14, 2011 |  BC Week In Review  |  Company News

Kinetic Concepts deal

Private equity group Apax Partners , along with affiliates of Canada Pension Plan Investment Board and the Public Sector Pension Investment Board, completed the acquisition of Kinetic Concepts for $68.50 per share in cash, or...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Company News

Kinetic Concepts deal

Private equity group Apax Partners, along with affiliates of Canada Pension Plan Investment Board and the Public Sector Pension Investment Board, will acquire Kinetic Concepts for $68.50 per share in cash, or about $6.3 billion...
07:00 , Apr 18, 2011 |  BioCentury  |  Strategy

Supercharging Astex

SuperGen Inc. and Astex Therapeutics Ltd. are betting that by combining the former's cash with the latter's pipeline and drug discovery platform, they can create a mid-tier cancer company. SuperGen has plenty of cash from...
07:00 , Jun 14, 2010 |  BC Week In Review  |  Company News

UCB, Wilex deal

UCB increased it stake in Wilex to 18.05% from 11.4% through the purchase of about 1.1 million shares at an undisclosed price from private equity firm Apax Partners . Wilex has rights to 5 UCB...
07:00 , Jun 14, 2010 |  BioCentury  |  Finance

Apax finishes exit

Apax finishes exit Private equity group Apax Partners , one of the biggest backers of European biotech startups in the 1990s, finished its ongoing exit of the sector by selling its stake in Wilex AG...
00:49 , Apr 8, 2009 |  BC Extra  |  Financial News

Aerovance raises $20 million

Aerovance Inc. (Berkeley, Calif.) raised $20 million in the first tranche of a planned $38 million private round led by new investor ProQuest Investments. BB Biotech Ventures, also a new investor, and existing investors Apax...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
08:00 , Dec 24, 2007 |  BioCentury  |  Finance

Ebb & Flow

GlaxoSmithKline (LSE:GSK; GSK) lost £1.27 billion ($2.6 billion) in market cap Monday on news that FDA's Center for Biologics Evaluation and Research had issued a complete response letter for the company's Cervarix HPV vaccine. The...
08:00 , Nov 12, 2007 |  BioCentury  |  Finance

Ebb & Flow

Onyx (ONXX) soundly beat the 3Q07 consensus EPS estimate of a $0.21 loss per share last week, turning a bit of a profit at $0.01 a share. The surprise came because analysts hadn't accounted for...